Spots Global Cancer Trial Database for Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Official Title: An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Study ID: NCT02516813
Conditions
Study Description
Brief Summary: MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research site, Fresno, California, United States
Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States
University of Miami Miller School of Medicine, Miami, Florida, United States
Research site, Billings, Montana, United States
Montefiore Medical Center PRIME, Bronx, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
Research site, Houston, Texas, United States
Research site, Tacoma, Washington, United States
Research site, Leuven, , Belgium
Rigshospitalet - PARENT, Copenhagen, , Denmark
Herlev Hospital - PARENT, Herlev, , Denmark
Research site, Freiburg, Baden Wuerttemberg, Germany
Charite Research Organisation GmbH - Phase - I Unit of Hematology and Oncology, Berlin, , Germany
Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, , Germany
Universitaetsklinikum Essen - Westdeutsches Tumorzentrum, Essen, , Germany
Universitaetsklinikum Heidelberg - RadioOnkologie und Strahlentherapie, Heidelberg, , Germany
Universitaetsklinikum Schleswig-Holstein - Campus Kiel - Klinik für diagnostische Radiologie, Kiel, , Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - Klinik und Poliklinik fuer Radiologie, Mainz, , Germany
Klinikum Mannheim GmbH Universitaetsklinikum - Parent, Mannheim, , Germany
Universitaetsklinikum Tuebingen - Medizinische Klinik I, Tuebingen, , Germany
Research site, Amsterdam, , Netherlands
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, , Netherlands
Research site, Oslo, , Norway
Karolinska universitetssjukhuset - Solna - Radiumhemmet (onkologi), Solna, , Sweden
Universitaetsspital Zuerich - Parent, Zuerich, , Switzerland
Contact Details
Name: Medical Responsible
Affiliation: Merck KGaA, Darmstadt, Germany
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
